Veracyte, INC Form 4 insider transactions

Rebecca Chambers, CFO of Veracyte, Inc., reports the withholding of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.

Veracyte's VP, Chief Accounting Officer Jonathan Wygant, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Veracyte's CEO, Marc Stapley, reports the withholding of common stock to cover tax obligations related to the vesting of restricted stock units.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Director Thomas F. Miller acquired 16,507 restricted stock units of Veracyte, Inc. on September 3, 2024.

Director David Brent Shafer of Veracyte, Inc. reports acquisition of 16,507 shares of common stock through restricted stock units.

Director Evan Jones reported multiple sales of Veracyte (VCYT) common stock and exercised stock options, executed under a pre-arranged 10b5-1 trading plan.

Director Evan Jones exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.

Director Evan Jones amended a previous Form 4 filing to clarify the breakdown of common stock sales executed under a Rule 10b5-1 plan.

Director Jens Holstein of Veracyte, Inc. executed sales of common stock on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Evan Jones exercised stock options and sold shares of Veracyte (VCYT) common stock on August 7, 2024, under a pre-arranged 10b5-1 trading plan.

Karin Eastham, a director at Veracyte, Inc., sold 7,500 shares of common stock at $25 per share on July 16, 2024, according to a Form 4 filing with the SEC.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., sold 1,277 shares of common stock at $25 per share on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jens Holstein sold 5,000 shares of Veracyte (VCYT) common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Evan Jones reports acquisition of restricted stock units and disposal of common stock.

Director Eliav Barr reports acquiring and disposing of Veracyte, Inc. common stock and receiving restricted stock units.

Director Jens Holstein reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024.

Director Muna Bhanji reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024, according to a Form 4 filing with the SEC.

Director Robert Epstein acquired 11,473 shares of Veracyte common stock and was granted restricted stock units vesting on the first anniversary or upon a change in control.

Director Karin Eastham reports acquiring and disposing of Veracyte, Inc. common stock on June 13, 2024, according to a Form 4 filing.

Karin Eastham, a director at Veracyte, Inc., sold 3,870 shares of common stock at a price of $20.59 on June 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Muna Bhanji sold 3,870 shares of Veracyte (VCYT) common stock at an average price of $20.3188, according to a Form 4 filing with the SEC.

Director Karin Eastham exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.

Rebecca Chambers, CFO of Veracyte, reports the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Veracyte's CEO, Marc Stapley, reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports the withholding of common stock to cover tax obligations related to vesting restricted stock units.

Director Muna Bhanji of Veracyte, Inc. executed a sale of 1,539 common stock shares at $21 per share on May 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.